Literature DB >> 20571391

Reprogramming adult hematopoietic cells.

Shin Kaneko1, Makoto Otsu, Hiromitsu Nakauchi.   

Abstract

PURPOSE OF REVIEW: Recent advances in molecular biology research have culminated in development of technologies to generate pluripotent stem cells from somatic cells. In addition to skin fibroblasts, hematopoietic cells also have been shown to be amenable to reprogramming to pluripotency. The present review discusses the relevance of these findings to basic researches and regenerative medicine, and how researchers can take advantage of hematopoietic cell reprogramming technologies. RECENT
FINDINGS: In 2006, Yamanaka and his colleagues published their amazing observation that murine somatic cells can be reprogrammed to the embryonic stem cell-like state simply by retroviral-mediated introduction of three or four defined factors. Soon after, human cells also were shown to be amenable to similar reprogramming. Generation of induced pluripotent cells from several types of hematopoietic cells of both murine and human origins now has been reported.
SUMMARY: Reprogramming adult hematopoietic cells will provide opportunities to obtain valuable materials with minimum risk and burden to patients. Reprogrammed cells can be used in research to elucidate disease mechanisms and in drug or toxicity screening. In clinical settings, patient-derived induced pluripotent stem cells may be used to generate mature functional cells for various therapies.

Entities:  

Mesh:

Year:  2010        PMID: 20571391     DOI: 10.1097/MOH.0b013e32833a25ee

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  2 in total

1.  Genetically matched human iPS cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin.

Authors:  Akira Nasu; Makoto Ikeya; Takuya Yamamoto; Akira Watanabe; Yonghui Jin; Yoshihisa Matsumoto; Kazuo Hayakawa; Naoki Amano; Shingo Sato; Kenji Osafune; Tomoki Aoyama; Takashi Nakamura; Tomohisa Kato; Junya Toguchida
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

Review 2.  Implications and limitations of cellular reprogramming for psychiatric drug development.

Authors:  Brian T D Tobe; Michael G Brandel; Jeffrey S Nye; Evan Y Snyder
Journal:  Exp Mol Med       Date:  2013-11-15       Impact factor: 8.718

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.